TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9678535
Drug: Small iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Small iodine supplements (Thyrojod depot tablets containing 1530 microg iodide) every 2 weeks for 2 years followed by once weekly for 2 years.
Study: 9678535
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iodine supplements).
Study: 9678535
Drug: Small iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Small iodine supplements (Thyrojod depot tablets containing 1530 microg iodide).
Study: 8034818
Drug: Balanced Deficit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced Deficit Diet (BDD) - 1,200-kcal/day diet throughout treatment
Study: 2648767
Drug: 200‐300 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐300 mg/day of trazodone
Study: 2648767
Drug: 200‐300 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐300 mg/day trazodone plus 1 ampoule (1000 gamma of lipidic phosphorous) twice daily of hypothalamic phospholipids (HPL)
Study: 22390966
Drug: Disease targeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease targeting therapies (DTT)
Study: 22390966
Drug: Escalation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation of therapy
Study: 19389004
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg on-demand 0.75-2 hours before sexual stimulation
Study: 16774799
Drug: Elemental oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental oral nutrition supplements
Study: 16774799
Drug: Peptide oral
Normalized name: Fe heme polypeptide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide oral nutrition supplements
Study: 16774799
Drug: Polymeric oral
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymeric oral nutrition supplements
Study: 11207404
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg intramuscularly
Study: 11207404
Drug: Meperidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 1.5 mg/kg (max 100 mg) intramuscularly
Study: 9278654
Drug: Aprotinin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (loading dose of 2 x 10(6) KI units followed by 0.5 x 10(6) KI units/h)
Study: 3725504
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion administered at a constant rate for 24 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Study: 3725504
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion administered at a constant rate for 16 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Study: 3725504
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion administered at a constant rate of 4 g/kg for 24 hours
Study: 3725504
Drug: Infusion rates
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rates as used in the study
Study: 3725504
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of fat at a constant rate for 24 hours
Study: 26698676
Drug: Fertility medication
Normalized name: Tests for fertility disturbances
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fertility medication (selective estrogen receptor modulator, gonadotropin, or other) or infertility treatment (IVF or IUI)
Study: 24584875
Drug: Standard external
Normalized name: CATHETER,EXTERNAL STANDARD BARD #150503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard external beam radiation therapy (EBRT)
Study: 20926027
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C (0.06 g/kg bolus followed by 0.02 g/kg)
Study: 12196880
Drug: Parenteral oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral oxytocin (5 units i.v. or 10 units i.m.)
Study: 10223249
Drug: CA125 elevation
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA125 elevation (> or =30 U/mL)
Study: 10223249
Drug: CA125 <30
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA125 <30 U/mL
Study: 2129633
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg omeprazole o.m.
Study: 8824652
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole o.m.
Study: 8824652
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole o.m.
Study: 2129633
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of omeprazole
Study: 2129633
Drug: Drug-induced hypochlorhydria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-induced hypochlorhydria
Study: 21247663
Drug: Polysporin first‐aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysporin first‐aid ointment (Poly/Bac)
Study: 19570440
Drug: Motherwort injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motherwort injection (40 mg uterine injection during CS and 20 mg intramuscular injection per 12 hours 3 times after CS)
Study: 19570440
Drug: Motherwort +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motherwort + Oxytocin (40 mg motherwort and 10 U oxytocin uterine injection during CS; 20 mg motherwort intramuscular injection per 12 hours 3 times after CS)
Study: 19570440
Drug: Oxytocin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (10 U uterine injection and 10 U+5% glucose 500 ml intravenously during operation; 10 U intramuscular injection per 12 hours 3 times after CS)
Study: 19570440
Drug: Motherwort injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motherwort injection
Study: 15928300
Drug: 8 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 Gy in one treatment fraction
Study: 15928300
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy in 10 treatment fractions
Study: 12711105
Drug: Chloroquine 25
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 25 mg base/kg given unsupervised by mothers at home
Study: 12711105
Drug: Chloroquine 25
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 25 mg base/kg given supervised at a health centre
Study: 8911949
Drug: Pilocarpine TDS
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine TDS (30 mg)
Study: 1921686
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 mg) and Propranolol (80 mg)
Study: 1921686
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (Diltiazem and Propranolol) after placebo
Study: 7029290
Drug: Adriamycin (ADR)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADR) 30 mg/m2/day for 3 successive days every 4 weeks for 6 courses
Study: 7029290
Drug: Alternating Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternating Adriamycin (ADR) and high-dose methotrexate followed by citrovorum factor rescue (HDMTX-CFR)
Study: 27707001
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of fentanyl citrate and propofol lipid emulsion (PLE)
Study: 27707001
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of fentanyl citrate and propofol lipid emulsion (PLE)
Study: 18564281
Drug: 0.05% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% capsaicin gel applied once daily for 5 months
Study: 18564281
Drug: Vehicle (control)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (control) applied once daily for 5 months
Study: 12220694
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with folic acid and vitamin B12
Study: 7709405
Drug: CGS 19755
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 19755 (1.5 mg/kg)
Study: 7709405
Drug: CGS 19755
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 19755 (2 mg/kg)
Study: 7709405
Drug: CGS 19755
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 19755 (1.75 mg/kg)
Study: 7709405
Drug: CGS 19755
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 19755 (1.0 mg/kg)
Study: 7709405
Drug: CGS 19755
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 19755 (all doses)
Study: 620896
Drug: Glucagon, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon, 2 mg given intravenously before aspirin instillation
Study: 620896
Drug: Glucagon, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon, 2 mg given intravenously
Study: 620896
Drug: Aspirin, 600
Normalized name: Aspirin, 600 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 600 mg suspended in 100 ml of isotonic saline
Study: 31200945
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein supplementation (30 grams of whey, three days/week during dialysis)
Study: 31200945
Drug: Protein plus
Normalized name: Nutritional Supplement Oral Tablet [SAMSON PROTEIN PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein plus exercise (30-45 minutes of cycling during dialysis treatment, three days/week)
Study: 21104227
Drug: Alendronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (35 mg weekly)
Study: 21104227
Drug: Elcatonin (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elcatonin (intramuscular 20 units a week)
Study: 19059753
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy with Attention Training (CBGT + ATT)
Study: 15509131
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg and HCTZ 12.5 mg once daily (n=46)
Study: 15509131
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg alone once daily (n=46)
Study: 3316516
Drug: Polychemotherapy as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polychemotherapy as initial therapy
Study: 3316516
Drug: Single new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single new drug
Study: 23386757
Drug: Intralesional steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroids
Study: 30227659
Drug: Tocovid 200
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tocovid 200 mg twice a day
Study: 27613934
Drug: Active progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active progesterone (PRO; 200mg twice a day)
Study: 18085502
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) treatment for 6 months
Study: 9536981
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression devices (Group 1)
Study: 9536981
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (Group 2)
Study: 8021331
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD 300 mg
Study: 4900147
Drug: Topical ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ampicillin powder
Study: 4900147
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo powder (lactose)
Study: 20006256
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen (100 mcg)
Study: 17171539
Drug: Family‐based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family‐based cognitive behavioural treatment for anxiety
Study: 11340513
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% povidone-iodine solution applied on the periocular skin and 5% povidone-iodine solution instilled on the forniceal conjunctiva the day before and one hour before surgery.
Study: 3295676
Drug: Meclofenamate therapy
Normalized name: meclofenamate
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate therapy
Study: 31046405
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg/d for 3 days, then 250 mg/2 days for 3 months)
Study: 3320880
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 10 mg intramuscular morphine and 10 mg oral cocaine
Study: 3320880
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine and cocaine
Study: 20432354
Drug: Magnetic resonance
Normalized name: MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic resonance angiography (MRA) using 20 mL of gadobenate dimeglumine
Study: 17257431
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied 3 times a week for 4 weeks
Study: 11806480
Drug: Acid-etching with
Normalized name: Q-Gel with Lipoic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-etching with 35% phosphoric acid gel
Study: 9486674
Drug: Moclobemide 450
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 450 mg/day + topical corticosteroid (diflucortolone valerate) for 6 weeks
Study: 9486674
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + topical corticosteroid (diflucortolone valerate) for 6 weeks
Study: 16856320
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (90 mg)
Study: 3143511
Drug: Transdermal patches
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patches containing 0.2 mA electrical current (active)
Study: 3143511
Drug: Transdermal patches
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patches containing no electrical current (passive)
Study: 31387381
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment (n = 27 feet) with foot-ankle-hip exercise program, myofascial releasing, and joint and soft tissue mobilization techniques, twice a week for 8 weeks.
Study: 24554545
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol, ketamine, and dexmedetomidine
Study: 22397344
Drug: Community care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community care (CC) group
Study: 20089952
Drug: Oral fingolimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fingolimod 0.5 mg daily
Study: 20089952
Drug: Oral fingolimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fingolimod 1.25 mg daily
Study: 17592343
Drug: 4 mg/d
Normalized name: Neupro 4 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/d of recombinant human growth hormone (r-hGH) for 12 weeks
Study: 17592343
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of r-hGH on alternate days for maintenance (weeks 12-36)
Study: 17533709
Drug: School-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based oral health education program
Study: 10561055
Drug: MSSW with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSSW with 0.2 g/L mineral content
Study: 10561055
Drug: MSSW with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSSW with 0.45 g/L mineral content
Study: 10561055
Drug: MSSW with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSSW with 5 g/L mineral content
Study: 10561055
Drug: MSSW with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSSW with 11 g/L mineral content
Study: 6350412
Drug: Plc (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plc (traditional pilocarpine salt solution)
Study: 31382136
Drug: High-dose prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisone monotherapy (60 mg/day)
Study: 31382136
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-dose prednisone and moderate-dose topiramate (5 mg/kg/day)
Study: 16036029
Drug: Beta-blockers (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (specific dosage not mentioned)
Study: 16036029
Drug: Suboptimal doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal doses of beta-blockers
Study: 16036029
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of beta-blockers (target doses from large-scale studies)
Study: 12585015
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal treatment early in psychosis
Study: 10467265
Drug: Approximately 0.34T,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 0.34T, 30 stimuli, twice a day
Study: 10467265
Drug: Approximately 0.57T,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 0.57T, 30 stimuli, twice a day
Study: 10467265
Drug: Approximately 0.80T,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 0.80T, 30 stimuli, twice a day
Study: 7589044
Drug: pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 40 mg o.d. for 8 weeks
Study: 1701029
Drug: A‐64077 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐64077 (800 mg)
Study: 27311618
Drug: Vigorous intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigorous intravenous fluid resuscitation (IVFR) with lactated Ringer's solution (initial bolus of 10 mL/kg before the procedure, 3 mL/kg/h during the procedure, for 8 hours after the procedure, and a post‐procedure bolus of 10 mL/kg)
Study: 27311618
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous fluid resuscitation (IVFR) with lactated Ringer's solution at 1.5 mL/kg/h during and for 8 hours after the procedure
Study: 20094804
Drug: Overall change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall change in daily UI episodes
Study: 17007699
Drug: Problem-solving treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving treatment for primary care (PST-PC) combined with elements from motivational interviewing
Study: 11051189
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine (100 mg in 50 cc of saline)
Study: 31061021
Drug: Current clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current clinical practice (300 U/mL)
Study: 31061021
Drug: NMJ-targeted injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMJ-targeted injection (100 U/mL)
Study: 30594222
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 162 mg administered subcutaneously once weekly for 24 weeks
Study: 30594222
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously once weekly for 24 weeks
Study: 27391223
Drug: Amlodipine, Chlorthalidone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine, Chlorthalidone, or Lisinopril (antihypertensive treatment)
Study: 22471345
Drug: Tacrolimus 1.5-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 1.5-3 ng/ml
Study: 22471345
Drug: Tacrolimus 4-7
Normalized name: tacrolimus 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 4-7 ng/ml
Study: 10886047
Drug: Effervescent ranitidine
Normalized name: ranitidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent ranitidine 150 mg b.d.
Study: 10886047
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate antacids
Study: 9376042
Drug: Pentoxifylline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1 mg/kg/h after a priming dose of 1 mg/kg)
Study: 9376042
Drug: Gamma-hydroxybutyrate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-hydroxybutyrate (25 mg/kg/h after a priming dose of 25 mg/kg)
Study: 8322373
Drug: Recombinant tissue‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue‐type plasminogen activator (0.85 mg/kg) within 90 minutes
Study: 8322373
Drug: Recombinant tissue‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue‐type plasminogen activator (0.85 mg/kg) from 91 to 180 minutes
Study: 3539623
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil 200 mg once daily
Study: 3539623
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil 200 mg twice daily
Study: 31061057
Drug: Conventional training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional training (maximal pelvic floor muscle contraction assessed by digital rectal examination)